Access the full text.
Sign up today, get DeepDyve free for 14 days.
Benjamin Jacobs, Anne Cain-Nielsen, Jill Jakubus, J. Mikhail, J. Fath, S. Regenbogen, M. Hemmila (2017)
Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in traumaJournal of Trauma and Acute Care Surgery, 83
M. Rothberg, P. Pekow, M. Lahti, P. Lindenauer (2012)
Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.Journal of hospital medicine, 7 6
Samuel Goldhaber (1999)
Venous Thromboembolism Prophylaxis in Medical PatientsThrombosis and Haemostasis, 82
M. Hillbom, T. Erilä, K. Sotaniemi, T. Tatlisumak, S. Sarna, M. Kaste (2002)
Enoxaparin vs heparin for prevention of deep‐vein thrombosis in acute ischaemic stroke: a randomized, double‐blind studyActa Neurologica Scandinavica, 106
D. Cook, M. Meade, G. Guyatt, S. Walter, D. Heels-Ansdell, T. Warkentin, N. Zytaruk, M. Crowther, W. Geerts, D. Cooper, S. Vallance, I. Qushmaq, Marcelo Rocha, O. Berwanger, N. Vlahakis (2011)
Dalteparin versus unfractionated heparin in critically ill patients.The New England journal of medicine, 364 14
A. Shorr, Mark Williams (2008)
Venous thromboembolism in critically ill patientsThrombosis and Haemostasis, 101
Jean-Fraçois Bergmann, E. Neuhart (1996)
A Multicenter Randomized Double-blind Study of Enoxaparin Compared with Unfractionated Heparin in the Prevention of Venous Thromboembolic Disease in Elderly In-patients Bedridden for an Acute Medical IllnessThrombosis and Haemostasis, 76
(2010)
Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity scoreAm J Epidemiol, 172
F. Kleber, C. Witt, G. Vogel, K. Koppenhagen, U. Schomaker, C. Flosbach (2003)
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.American heart journal, 145 4
(2008)
Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)Chest, 133
S. Kahn, W. Lim, A. Dunn, M. Cushman, F. Dentali, E. Akl, E. Akl, D. Cook, A. Balekian, Russell Klein, Hoang Le, Hoang Le, S. Schulman, M. Murad (2012)
Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest, 141 2 Suppl
H. Schünemann, M. Cushman, Allison Burnett, S. Kahn, J. Beyer-Westendorf, F. Spencer, S. Rezende, N. Zakai, K. Bauer, F. Dentali, Jill Lansing, S. Balduzzi, A. Darzi, G. Morgano, I. Neumann, R. Nieuwlaat, J. Yepes-Nuñez, Yuan Zhang, W. Wiercioch (2018)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.Blood advances, 2 22
S. Fernando, Alexandre Tran, Wei Cheng, B. Sadeghirad, Y. Arabi, D. Cook, M. Møller, S. Mehta, R. Fowler, K. Burns, P. Wells, M. Carrier, M. Crowther, D. Scales, S. English, K. Kyeremanteng, S. Kanji, M. Kho, B. Rochwerg (2021)
Venous Thromboembolism Prophylaxis in Critically Ill Adults - A Systematic Review and Network Meta-Analysis.Chest
(Improved Race, Ethnicity Measures Show U.S. is More Multiracial. https://www.census.gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html. Accessed 23 June 2022)
Improved Race, Ethnicity Measures Show U.S. is More Multiracial. https://www.census.gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html. Accessed 23 June 2022Improved Race, Ethnicity Measures Show U.S. is More Multiracial. https://www.census.gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html. Accessed 23 June 2022, Improved Race, Ethnicity Measures Show U.S. is More Multiracial. https://www.census.gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html. Accessed 23 June 2022
J. Harenberg, P. Roebruck, D. Heene (1996)
Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group.Haemostasis, 26 3
Anushtup De, Prabal Roy, Vinod Garg, N. Pandey (2010)
Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgeryBlood Coagulation & Fibrinolysis, 21
W. Alhazzani, W. Lim, R. Jaeschke, M. Murad, J. Cade, D. Cook (2013)
Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*Critical Care Medicine, 41
P. Sandercock, T. Leong (2017)
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.The Cochrane database of systematic reviews, 4
P. Austin
American Journal of Epidemiology Practice of Epidemiology Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-one Matching on the Propensity Score
S. Laporte, J. Liotier, L. Bertoletti, F. Kleber, G. Pineo, C. Chapelle, N. Moulin, P. Mismetti (2011)
Individual patient data meta‐analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patientsJournal of Thrombosis and Haemostasis, 9
D. Sherman, G. Albers, C. Bladin, C. Fieschi, A. Gabbai, C. Kase, W. O'Riordan, G. Pineo (2007)
The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparisonThe Lancet, 369
Prevalence of PE between patients receiving enoxaparin (red) compared to heparin (blue)
E. Lechler, W. Schramm, C. Flosbach (1996)
The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group.Haemostasis, 26 Suppl 2
(Appendix C: VTE Measurement and Tracking | Agency for Healthcare Research and Quality. https://www.ahrq.gov/patient-safety/resources/vtguide/appc.html. Accessed 25 June 2022)
Appendix C: VTE Measurement and Tracking | Agency for Healthcare Research and Quality. https://www.ahrq.gov/patient-safety/resources/vtguide/appc.html. Accessed 25 June 2022Appendix C: VTE Measurement and Tracking | Agency for Healthcare Research and Quality. https://www.ahrq.gov/patient-safety/resources/vtguide/appc.html. Accessed 25 June 2022, Appendix C: VTE Measurement and Tracking | Agency for Healthcare Research and Quality. https://www.ahrq.gov/patient-safety/resources/vtguide/appc.html. Accessed 25 June 2022
C. Pawlowski, A. Venkatakrishnan, C. Kirkup, G. Berner, A. Puranik, J. O’Horo, A. Badley, V. Soundararajan (2021)
Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patientsEClinicalMedicine, 33
(R Core Team (2020) European Environment Agency. https://www.eea.europa.eu/data-and-maps/indicators/oxygen-consuming-substances-in-rivers/r-development-core-team-2006. Accessed 25 June 2022)
R Core Team (2020) European Environment Agency. https://www.eea.europa.eu/data-and-maps/indicators/oxygen-consuming-substances-in-rivers/r-development-core-team-2006. Accessed 25 June 2022R Core Team (2020) European Environment Agency. https://www.eea.europa.eu/data-and-maps/indicators/oxygen-consuming-substances-in-rivers/r-development-core-team-2006. Accessed 25 June 2022, R Core Team (2020) European Environment Agency. https://www.eea.europa.eu/data-and-maps/indicators/oxygen-consuming-substances-in-rivers/r-development-core-team-2006. Accessed 25 June 2022
(2022)
Appendix C: VTE Measurement and Tracking | Agency for Healthcare Research and Quality. https:// www. ahrq. gov/ patie ntsafety/ resou rces/ vtgui de/ appc
Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are often administered to prevent venous thromboembolism (VTE) in critically ill patients. However, the preferred prophylactic agent (UFH or LMWH) is not known. We compared the all-cause mortality rate in patients receiving UFH to LMWH for VTE prophylaxis. We conducted a retrospective propensity score adjusted analysis of patients admitted to neuro-critical, surgical, or medical intensive care units. Patients were included if they were screened with venous duplex ultrasonography or computed tomography angiography for detection of VTE. The primary outcome was all-cause mortality. Secondary outcomes included the prevalence of VTE, deep vein thrombosis (DVT), pulmonary embolism (PE), and hospital length of stay (LOS). Initially 2228 patients in the cohort were included for analysis, 1836 (82%) patients received UFH, and 392 (18%) patients received enoxaparin. After propensity score matching, a well-balanced cohort of 618 patients remained in the study (309 patients receiving UFH; 309 patients receiving enoxaparin). The use of UFH for VTE prophylaxis in ICU patients was associated with similar rates of all-cause mortality compared with enoxaparin [RR 0.73; 95% CI 0.43–1.24, p = 0.310]. There were no differences in the prevalence of DVT, prevalence of PE or hospital LOS between the two groups, DVT [RR 0.93; 95% CI 0.56–1.53, p = 0.889], PE [RR 1.50; 95% CI 0.78–2.90, p = 0.296] and LOS [9 ± 9 days vs 9 ± 8; p = 0.857]. A trend toward mortality benefit was observed in NICU [RR 0.37; 95% CI 0.13–1.07, p = 0.062] and surgical patients [RR 0.43; 95% CI 0.17–1.02, p = 0.075] favoring the enoxaparin group. The use of UFH for VTE prophylaxis in ICU patients was associated with similar rates of VTE, all-cause mortality and LOS compared to enoxaparin. In subgroup analysis, neuro-critical and surgical patients who received UFH had a higher rate of mortality than those who received enoxaparin.
Journal of Thrombosis and Thrombolysis – Springer Journals
Published: Apr 1, 2023
Keywords: Deep vein thrombosis; Pulmonary embolism; Mortality; Venous thromboembolism prophylaxis; Unfractionated heparin; Low molecular weight heparin
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.